Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.
Campus
Campus

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Practical Approach in Understanding PN Pathophysiology

Practical Approach in Understanding PN Pathophysiology

This video highlights prurigo nodularis (PN) as a systemic disorder driven by neural inflammation and immune dysregulation. Key inflammatory mediators IL-4 and IL-13, along with fibrosis, emerge as central features, emphasizing the need for targeted therapies that address both neural and immune pathways. 

Learn more
Clinical Indicators of COPD: A GOLD Guidelines Review

Clinical Indicators of COPD: A GOLD Guidelines Review

This video highlights the key insights from the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, presenting a clear, structured, and evidence-based approach to the diagnosis, assessment, and management of COPD.

Learn more
Adaptive Eating Behaviors in EoE

Adaptive Eating Behaviors in EoE

Learn more
Pediatric EoE: Indicators for Early Diagnosis and Intervention

Pediatric EoE: Indicators for Early Diagnosis and Intervention

Learn more
Nirsevimab RWD Metanalysis

Nirsevimab RWD Metanalysis

Learn more
Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)

Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)

Learn more
Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results

Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results

Learn more
Patient morbidity and mortality in BP

Patient morbidity and mortality in BP

Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more

Learn more
What is Bullous Pemphigoid

What is Bullous Pemphigoid

The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more

Learn more
Treatments and challenges for bullous pemphigoid

Treatments and challenges for bullous pemphigoid

Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more

Learn more
Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more

Learn more
Mechanism of Smoldering Disease

Mechanism of Smoldering Disease

Learn more